Cartesian Therapeutics Files 8-K
Ticker: RNAC · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Cartesian Therapeutics filed an 8-K on Jan 27, 2025, mostly procedural stuff.
AI Summary
On January 27, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Cartesian Therapeutics, Inc. is providing updates or submitting required documentation to the SEC, which could relate to ongoing operations or financial reporting.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing cover page and does not contain information about material events, financial performance, or significant risks.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- January 27, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Cartesian Therapeutics, Inc.?
The filing is categorized under "Other Events" and "Financial Statements and Exhibits," indicating it pertains to updates or required submissions to the SEC.
When was this 8-K report filed?
The report was filed on January 27, 2025.
What is the principal executive office address for Cartesian Therapeutics, Inc.?
The address is 7495 New Horizon Way, Frederick, MD 21703.
What is the Commission File Number for Cartesian Therapeutics, Inc.?
The Commission File Number is 001-37798.
Does the filing mention any specific financial results or material business developments?
The provided excerpt of the 8-K filing does not detail specific financial results or material business developments.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-27 07:04:17
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
Filing Documents
- rnac-20250127.htm (8-K) — 30KB
- pressrelease012725.htm (EX-99.1) — 15KB
- cartesian_logoxcolorxcmyk.jpg (GRAPHIC) — 1239KB
- 0001453687-25-000050.txt ( ) — 1807KB
- rnac-20250127.xsd (EX-101.SCH) — 2KB
- rnac-20250127_lab.xml (EX-101.LAB) — 21KB
- rnac-20250127_pre.xml (EX-101.PRE) — 12KB
- rnac-20250127_htm.xml (XML) — 3KB
01. Other Information
Item 8.01. Other Information. On January 27, 2025, Cartesian Therapeutics, Inc. (the "Company") issued a press release announcing that it has received written agreement from the U.S. Food and Drug Administration under the Special Protocol Assessment process on the overall design of the Company's Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Press release of Cartesian Therapeutics, Inc. issued on January 27, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: January 27, 2025 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer